These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 22790041

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
    Kubota O, Onuki Y, Uchiyama T, Oishi K, Takeda M.
    Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N, Kimura M, Kobayashi Y, Asahara F, Hayashi K, Shibata S, Shintoku J.
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The clinical benefit of high-dose toremifene for metastatic breast cancer.
    Koike K, Edo M, Higaki M, Kitahara K, Satou S, Noshiro H.
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
    [Abstract] [Full Text] [Related]

  • 7. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
    Ogata H, Okamoto Y, Arima Y, Fukushima H, Takeyama H, Yamashita A, Kinoshita M, Suzuki N, Sawada T, Koshida Y, Matsui A, Tachibana A, Nakayama H, Oishi Y, Nogi H, Uchida K.
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
    Sakurai K, Fujisaki S, Nagashima S, Maeda T, Tomita R, Suzuki S, Hara Y, Hirano T, Enomoto K, Amano S.
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer.
    Hietanen T, Hakala T, Baltina D, Johansson R, Numminen S, Helle L, Valavaara R, Thölix E.
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):37-40. PubMed ID: 9165505
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
    Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y, Iwase H.
    Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
    Sakurai K, Matsuo S, Enomoto K, Amano S, Shiono M.
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1994-6. PubMed ID: 20037302
    [Abstract] [Full Text] [Related]

  • 20. [A case of breast cancer with multiple bone metastases demonstrating complete remission with high-dose toremifene therapy].
    Saito Y, Amano S, Kashio M, Abe H, Kuboi Y, Sakurai K, Aoki N, Hata S, Negishi N.
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):911-4. PubMed ID: 15222111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.